Definium Therapeutics (DFTX) Operating Expenses (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Operating Expenses data on file, last reported at $59.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 84.15% year-over-year to $59.2 million in Q1 2026; TTM through Mar 2026 was $193.4 million, a 69.81% increase from a year earlier, with the FY2025 full-year figure at $166.3 million, up 60.04% from the prior year.
• Operating Expenses for Q1 2026 stood at $59.2 million, up from $47.6 million in the prior quarter.
• Over the last five years, Operating Expenses for DFTX reached as high as $59.2 million in Q1 2026 and fell as low as $13.9 million in Q4 2022.
• Historically, Operating Expenses has averaged $28.8 million across 5 years, with a median of $24.5 million in 2024.
• Across the five-year window, Operating Expenses plunged 62.53% in 2022 and jumped 84.21% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $13.9 million in 2022, then surged by 59.75% to $22.2 million in 2023, then surged by 46.19% to $32.5 million in 2024, then jumped by 46.57% to $47.6 million in 2025, then grew by 24.47% to $59.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $59.2 million in Q1 2026, $47.6 million in Q4 2025, and $45.7 million in Q3 2025.